Our guest editors for these two special issues on lung cancer are Prof Rafael Rosell, Head of the Medical Oncology Service at the Catalan Institute of Oncology, Badalona, Spain, and Chief Scientific Officer and Co-Founder of Pangaea Biotech S.L, Barcelona, Spain and Dr Niki Karachaliou from Pangaea Biotech, USP Instituto Universitario Dexeus, Barcelona, Spain.
These two special issues will focus on genetic etiology, diagnostic tools and management of lung cancer, providing explanations and educational information on lung cancer for the wider medical community. This two-issue series will feature key opinions from outstanding experts in lung cancer, presenting challenges and opportunities in radiotherapy, chemotherapy and targeted therapy, respectively. Offering a unique platform for the exploration of targeted treatment for lung cancer patients, these two issues will represent a unique collection of the most cutting edge literature on lung cancer from leading experts in the field.
The current outline for these two issues is as follows:
ISSUE ONE
ALK, ROS as a joint target for the treatment of lung cancer: A review
Authors: Jordi Texidó, Jose Ignacio Borell, Roger Estrada
Universal molecular screening: RNA sequence in clinical applications
Authors: Carlota Costa
Activating mutations clustered in the brake regions of kinases
Authors: Miguel Angel Molina
FGFR1 in squamous cell carcinoma of the lung
Authors: Jurgen Wolf, Reinhard Buttner
Copy number gains of FGFR1 and 3q in squamous cell carcinoma of the lung
Authors: Pedro Mendez, Jose Luis Ramirez
Management of ROS1 and RET translocated lung cancer
Authors: Jurgen Wolf, Reinhard Buttner, Niki Karachaliou, Irene Sansano, Carlota Costa
HER2 driven NSCLC, potential therapeutic approaches
Authors: Enriqueta Felip
Targeting EML4-ALK driven NSCLC
Authors: Teresa Moran
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach
Authors: Javier de Castro
ISSUE TWO
Whole genome sequencing and transcriptome characterization of lung cancer
Authors: Petros Giannikopoulos, Trever Bivona
Tumor heterogeneity, evolution through space and time: a rebiopsy study
Authors: Margarita Majem
Customizing adjuvant chemotherapy
Authors: Bartomeu Massuti, Jose Miguel Sanchez, Florentino Hernando-Trancho, Niki Karachaliou, Rafael Rosell
Worldwide trial with a 14-gene signature in high risk stage I non-squamous cell carcinoma
Author: David Jablons
Customizing chemotherapy in metastatic NSCLC
Authors: Jia Wei, Teresa Moran, Zhengyun Zou, Xiaoping Qian, Lifeng Wang, Carlos Camps, Wenjing Hu, Imane Chaib, Belén Sanchez, Lixia Xu, Niki Karachaliou, María Sanchez-Ronco, Baroui Liu, Rafael Rosell
What is the relevance of SOX2 in SCLC, lung adenocarcinoma and squamous cell carcinoma of the lung?
Authors: Niki Karachaliou, Santiago Viteri, Rafael Rosell
State of the art of radiotherapy
Authors: Pilar Garrido
Predictive models for customizing chemotherapy in advanced NSCLC
Authors: Laura Bonanno
Adaptive resistance to targeted therapies in cancer
Authors: Rafael Rosell, Niki Karachaliou, Daniela Morales-Espinosa
BRAF mutant NSCLC
Authors: Jose Miguel Sanchez, Santiago Viteri
Management of elderly patients
Authors: Alain Vergenengre